Last reviewed · How we verify

Prospective, Double-blind, Placebo-controlled, Randomized, Multi-center Trial With a Double-blind Parallel-group Extension Period to Investigate the Efficacy and Safety of Different Doses of IncobotulinumtoxinA (Xeomin) in the Treatment of Cervical Dystonia

NCT00407030 Phase 3 COMPLETED Results posted

At baseline patients received incobotulinumtoxinA (Xeomin) or placebo. Thereafter, all patients who entered the extension period were treated with up to five injection sessions of incobotulinumtoxinA (Xeomin) during the extension period.

Details

Lead sponsorMerz Pharmaceuticals GmbH
PhasePhase 3
StatusCOMPLETED
Enrolment233
Start date2006-07
Completion2009-06

Conditions

Interventions

Primary outcomes

Countries

United States